Werewolf Therapeutics, Inc. 8K

Werewolf Therapeutics reported Q2 2026 financial results driven by a $21 million asset sale to Jazz Pharmaceuticals, repaid its K2 debt, outlined its cash runway into Q2 2027, and confirmed an ongoing strategic alternatives review with Piper Sandler.

Werewolf Therapeutics, Inc. reported its second quarter 2026 financial results and provided a corporate update, highlighting the previously announced asset purchase agreement with Jazz Pharmaceuticals Ireland Limited for the JZP898 program and the repayment in full of its loan and security agreement with K2 HealthVentures LLC, which together generated a $21.0 million payment to Werewolf. The company recorded $21.0 million in collaboration revenue tied to the JZP898 sale, reduced research and development expenses year-over-year, increased general and administrative expenses, and achieved net income of $3.7 million for the quarter versus a prior-year net loss. Werewolf ended June 30, 2026 with $22.0 million in cash and cash equivalents and expects this to fund operations into the second quarter of 2027. Management also noted that strategic alternatives for the company’s INDUKINE and INDUCER platforms are being evaluated with the assistance of exclusive financial advisor Piper Sandler & Co., and that further updates on both the strategic review and clinical data from lead programs WTX-124 and WTX-330 are anticipated in the second half of the year, though no timeline or outcome can be assured.

Filing Facts

CIK

1785530

Ticker

-

Form

8K

Source Type

sec

Accession

0001785530-26-000018

Alert Tier

7